Global Circulating Tumor Cells (CTC) Market - 2024-2031

Circulating Tumor Cells Market Size

The Global Circulating Tumor Cells Market reached US$ 11.80 billion in 2023 and is expected to reach US$ 26.61 billion by 2031, growing at a CAGR of 11.1% during the forecast period 2024-2031.

Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor and intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive detection of CTCs from clinical samples can serve as an effective tool in cancer diagnosis and prognosis through liquid biopsy.

Current CTC detection technologies mainly reply on biomarker-mediated platforms including magnetic beads, microfluidic chips or size-sensitive microfiltration which can compromise detection sensitivity due to tumour heterogeneity. A more sensitive, biomarker-independent CTCs isolation technique has been recently developed with the surface-charged superparamagnetic nanoprobe capable of different EMT subpopulation CTC capture from 1 mL clinical blood.

Circulating Tumor Cells Market Drivers and Restraints

Increasing number of cancer cases

The increasing number of cancer cases is one of the significant key factors that help the market to grow during the forecast period. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favourable in men compared to women.

As cancer prevalence rises, there is a growing need for effective cancer diagnostics and monitoring tools along with CTC-based assays and technologies. This presents a significant opportunity for companies operating in the market to develop innovative products and solutions that enable the detection, enumeration, and molecular characterization of CTCs.

Additionally, the growing interest in liquid biopsy approaches further fuels the demand for CTC-based technologies, as they offer a non-invasive method for real-time monitoring of cancer patients.

Furthermore, the circulating tumor cells market is also driven by various other factors like, advancements in CTC detection technologies, increasing demand for rapid cancer diagnosis, development of targeted therapies and others will also help the market to grow during the forecast period.

Market Dynamics: Restraint

Various factors which hamper the market growth during the forecast period some which are Stringent regulatory framework, technical difficulties in CTC detection, cost containment measures, lack of knowledge about advanced CTC technologies, and time-consuming requirements for product launch approvals.

Circulating Tumor Cells Market Segment Analysis

The global circulating tumor cells market is segmented based on product type, technology, application, specimen, end user and region.

The devices segment from the product type segment accounted for approximately 43.5% of the circulating tumor cells market share

The devices from the product type segment accounted for approximately 43.5% and are expected to be dominated during the forecast period. This segment focuses on developing and utilizing devices specifically designed for CTC-related applications. To enhance technical capabilities and facilitate mass production, the market has witnessed the introduction of manufactured glass microchips, which address challenges and improve overall efficiency.

For instance, in June 2020, SCIENION AG and RareCyte Inc. stated that cellenONE proved to be the most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENIONOs French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.

Circulating Tumor Cells Market Geographical Share

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors like the increasing prevalence of cancer in the region coupled with advancements in diagnostic technologies as well as rising awareness among healthcare professionals has contributed to the flourishing CTCs market. Also, robust healthcare infrastructure, coupled with significant investments in research and development, has paved the way for innovative CTC detection and analysis techniques.

For instance, according to the estimates of the 2022, American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the circulating tumor cells market. The pandemic caused disruptions in healthcare systems worldwide, leading to delays in cancer screenings, diagnosis, and treatment. This, in turn, affected the demand for CTC-based tests and technologies. Moreover, restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in the adoption of CTC-based assays.

Circulating Tumor Cells Market Companies

The major global players in the market include Thermo Fisher Scientific Inc, QIAGEN, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., BioFluidica, Biolidics Limited, Creativ MicroTech Inc., Menarini Silicon Biosystems, StemCell Technologies among others.

Key Developments

In September 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market, stated the launch of its Portrait™ Flex CTC assay. The assay is provided as a service from ANGLE's Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with over 10 years of experience in CTC analysis.

In July 2023, Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single-cell technologies, stated the availability of its new CELLSEARCH CTC lab service to detect the expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream. This biomarker is mainly expressed in difficult-to-treat cancers. The new MSB lab service opens the door to the development of further minimally invasive tests that leverage the prognostic and predictive value of biomarkers in medical settings with high unmet needs.

In May 2021, ARUP Laboratories stated that it had signed a strategic agreement with Massachusetts-based TellBio Inc. to use the development-stage biotechnology company's TellDx circulating tumor cells (CTCs) technology in several research applications.

Why Purchase the Report?

To visualize the global circulating tumor cells market segmentation based on product type, technology, application, specimen, end user and region as well as understand key commercial assets and players.

Identify commercial opportunities by analysing trends and co-development.

Excel data sheet with numerous data points of circulating tumor cells market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global circulating tumor cells market report would provide approximately 77 tables, 79 figures and 187 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies